Loading data for IONS — first visit, this takes a few seconds.

Alerta

Ionis Pharmaceuticals Inc... (IONS)

NasdaqGS: IONS · Precio en tiempo real · USD

61.16

+1.54 (2.58%)

Al cierre: Aug 19, 2026, 7:02 PM

2.58% (1D)

No hay datos disponibles

Precio de compra	55.54
Capitalización de mercado	10.15B
Ingresos (TTM)	874.09M
Beneficio neto (TTM)	-565.17M
Beta	0.40
EPS (TTM)	-3.48
Ratio PER (TTM)	n/a
Adelante PE	-57.94
P/B (TTM)	23.01
P/S (TTM)	11.62
Earnings Date	Nov 4, 2026

Precio de venta	65.34
Volumen	1,798,865
Volumen medio (20D)	2,880,609
Abierto	60.20
Anterior Cerrar	59.62
Rango del día	59.61 - 61.19
Rango de 52 semanas	41.71 - 86.74
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de IONS

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) i...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha May 17, 1991

Empleados 1,480

Bolsa de Valores NasdaqGS

Símbolo bursátil IONS

Sitio web https://www.ionis.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Ionis Pharmaceuticals fueron 943.71M, un aumento de 33.83% en comparación con 705.14M del año anterior. Las ganancias fueron -381.39M, una disminución de -15.97%.

Estados financieros

Sorpresa de resultados

Ionis Pharmaceuticals ha publicado sus resultados trimestrales en Jul 29, 2026:

Ingresos de $267.95M falla las estimaciones por $0, con -40.73% Disminución interanual.

EPS de -0.42 supera las estimaciones en 0.46, con -149.41% Disminución interanual.

Próxima publicación de resultados

Está previsto que Ionis Pharmaceuticals Inc. publique sus resultados el Nov 4, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

3 días hace · Simply Wall St.

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past 3 months. That mixed pattern sets the stage for a...

5 días hace · Motley Fool

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

A drug that didn't meet expectations in a trial is to blame.

1 semana hace · Motley Fool

Ionis (IONS) Q2 2026 Earnings Call Transcript

Revenue hit $268 million with 56% growth, while TRYNGOLZA sales accelerated.

2 semanas hace · Motley Fool

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Insider holdings surged 34% through indirect acquisition, signaling confidence amid company's $8.8 billion valuation and RNA-therapy pipeline advancement.

2 semanas hace · Trefis

Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

Página 1 de 2

Ionis Pharmaceuticals Inc... (IONS)